Melanocortin Receptors: Unlocking New Therapies for Obesity and Cachexia
Background
The melanocortin system, centered around melanocortin receptors (MCRs), has been a focus of research for over 100 years due to its diverse physiological roles. While initial studies identified MSHR and ACTHR, three additional MCRs were later discovered, bringing the total to five. Among these, MC3R and MC4R are primarily found in the central nervous system and are crucial for regulating energy homeostasis. This review specifically addresses the current landscape of ligands targeting these neural MCRs for metabolic disease treatment.
Results
The review underscores the critical role of the central melanocortin system, particularly MC3R and MC4R, in regulating energy homeostasis, highlighting their potential as therapeutic targets. It details how early efforts in modifying endogenous ligands have successfully led to the development of many potent and selective compounds, with significant progress over the past century. The synthesis of current knowledge strongly supports targeting neural melanocortin receptors as a promising therapeutic strategy for managing metabolic conditions such as obesity and cachexia. The authors identify five distinct MCRs, with MC3R and MC4R being key neural targets, and illustrate the diverse array of ligands developed, from naturally occurring peptides to synthetic small molecules, showcasing the significant progress in the field.
Why It Matters
This review consolidates extensive research, providing a clear roadmap for future drug development targeting the melanocortin system. The identification of potent and selective ligands for MC3R and MC4R offers novel avenues for treating complex metabolic disorders. Given the success of compounds like setmelanotide (a MC4R agonist approved for rare genetic obesities), further development of these ligands could lead to new clinical treatments for broader populations suffering from obesity and cachexia. Future steps will likely involve advancing promising nonclassical ligands and small molecules into preclinical and potentially human clinical trials.